Association between serum alkaline phosphatase and C-reactive protein in the United States National Health and Nutrition Examination Survey 2005-2006

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 2, 2010, Pages 167-173

  Webber, Matthew ^a   Krishnan, Aisling ^a   Thomas, Neil G ^a   Cheung, Bernard M Y ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Alkaline phosphatase; C reactive protein; Cardiovascular disease; NHANES

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; ETHNICITY; EXERCISE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENDER; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HISPANIC; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGE FACTORS; ALKALINE PHOSPHATASE; BLOOD PRESSURE; BODY WEIGHTS AND MEASURES; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HEALTH SURVEYS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPIDS; LIVER; MALE; MULTIVARIATE ANALYSIS; NUTRITION SURVEYS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; UNITED STATES;

EID: 76649129005     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.052     Document Type: Article

References (33)

1. World Health Organization. Prevention of cardiovascular disease: guidelines for assessment and management of total cardiovascular risk. http://www.who.int/cardiovascular-diseases/guidelines/ Prevention-of- Cardiovascular-Disease/en/index.html. Accessed March 2008.
2. Kerner A, Avizohar O, Sella R, Bartha P, Zinder O, Markiewicz W, et al. Association between elevated liver enzymes and Creactive protein. Possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25:193-197
3. Libby P, Ridker M, Maseri AM. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143
4. Russel R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-126
5. Sumner AD, Eid S, Parks A, Edris B, Reed III JF. Increasing prevalence of peripheral artery disease in the United States: results from the national health and nutrition examination survey (1999-2004). Circulation wabstractx 2007;116:II-780.
6. Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol 2005;96:1579-1583
7. Vu JD, Vu JB, Pio JR, Malik S, Franklin SS, Chen RS, et al. Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol 2005;96:655-658
8. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565
9. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-Reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-978
10. Danesh J, Collins R, Appleby P. Association of fibrinogen, Creactive protein or leukocyte count with coronary heart disease: meta analysis of prospective studies. J Am Med Assoc 1998; 279:1477-1482
11. Festa A, D'Agostino R, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation 2000;102:42-47
12. Lane JS, Vittinghoff E, Lane KT, Hiramoto JS, Messina LM. Risk factors for premature peripheral vascular disease: results for the national health and nutritional survey, 1999-2002. J Vasc Surg 2006;44:319-324
13. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994;333:417-424
14. Ali AT, Penny CB, Paiker JE, Van Niekerk C, Smit A, Ferris WF, et al. Alkaline phosphatase is involved in the control of adipogenesis in the murine preadipocyte cell line, 3T3-L1. Clin Chim Acta 2005;354:101-109
15. Hanley AJ, Williams K, Fests A, Wagenknecht LE, D'Agostino RB, Haffner SM. Liver markers and the development of the metabolic syndrome. The insulin resistance atherosclerosis study. Diabetes 2005;54:3140-3147
16. Cheung BM, Ong KL, Cheung RV, Wong LY, Wat NM, Tam S, et al. Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese. Clin Chem Lab Med 2008;46:523-527
17. Cheung BM, Ong KL, Wong LY. Elevated serum alkaline phosphatase and peripheral arterial disease in the United States National Health and Nutrition Examination Survey 1999-2004. Int J Cardiol 2009;135:156-161
18. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005-2006. http://www.cdc.gov/nchs/ about/major/nhanes/datalink.htm. Accessed March 23, 2009.
19. Blayney MJ, Pisoni RL, Bragg-Gresham JL, Bommer J, Piera L, Saito A, et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int 2008;74:655-663
20. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, et al. C-Reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler Thromb Vasc Biol 2003;23:1255-1261
21. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of Creactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial. Am J Epidemiol 1996;144:537-547
22. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191:235-240 (Pubitemid 46400718)
23. Nasri H, Baradaran A, Naderi AS. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. Acta Med Austriaca 2004;31:67-72.
24. Salgueira M, Milan JA, Moreno Alba R, Amor J, Aresté N, Jiménez E, et al. Cardiac failure and diastolic dysfunction in hemodialysis patients: associated factors. Nefrologia 2005; 25:668-677
25. Ali AT, Penny CB, Paiker JE, Psaras G, Ikram F, Crowther NJ. The effect of alkaline phosphatase inhibitors on intracellular lipid accumulation in preadipocytes isolated from human mammary tissue. Ann Clin Biochem 2006;43:207-213 (Pubitemid 43668153)
26. Domar U, Karpe F, Hamsten A, Stigbrand T, Olivecrona T. Human intestinal alkaline phosphatase-release to the blood is linked to lipid absorption, but removal from the blood is not linked to lipoprotein clearance. Eur J Clin Invest 1993;23: 753-760
27. Narisawa S, Harmey D, Yadav MC, O'Neill WC, Hoylaerts MF, Millán JL. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 2007;22:1700-1710
28. Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, et al. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population: the Funagata study. Diabetes Care 2003;26:2015-2020
29. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007;49:1455-1461
30. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004;24:1161-1170
31. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int 2008;73:1024-1030
32. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503-511
33. Mora S, Ridker PM. Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006;97:33-41.